Key Highlights

  • Traws Pharma (NASDAQ:TRAW) rose 7.42% to about USD 0.3679 in early trading on Monday, October 26, 2026, after a USD 50 million equity purchase agreement with Roth Principal Investments, capped at 3,072,118 shares.
  • Innventure (NASDAQ:INV) fell about 10% to near USD 0.29 after setting up a USD 60 million at-the-market programme on Thursday, October 8, 2026, with USD 41.5 million of cash at the end of the second quarter.
  • authID (NASDAQ:AUID) fell 11.22% to below USD 0.40 after pricing about USD 1,350,000 of convertible debentures on Monday, October 5, 2026, convertible at USD 0.386 per share with warrants at USD 0.50.
  • All three trade under USD 1.00 and fund operations by issuing shares on terms that tie supply to price, which links each move to dilution and cash runway.

Traws Pharma (NASDAQ:TRAW): a standby line with a 19.99% cap

Traws Pharma (NASDAQ:TRAW), a clinical-stage biopharmaceutical company, traded 7.42% higher at about USD 0.3679 in early trading on Monday, October 26, 2026, which implies a prior close near USD 0.3425, calculated from the move. The catalyst is a common stock purchase agreement dated Friday, October 23, 2026 with Roth Principal Investments, LLC, under which the company may sell up to USD 50 million of new shares over about three years. The company controls timing and amount and has no obligation to sell.

An equity line is a standby arrangement in which an investor agrees to buy shares on demand at a formula price, here 6.0% below the volume weighted average price. Purchases at the open are limited to the lesser of 2 million shares or 25% of Nasdaq volume. Issuance is capped at 3,072,118 shares, equal to 19.99% of shares outstanding, which implies about 15.4 million shares and a market capitalisation near USD 5.7 million, calculated.

Selling the capped shares near USD 0.35 would raise roughly USD 1.1 million, calculated, far short of USD 50 million, so the full size depends on price gains or shareholder approval. Every sale adds shares at a discount, liquidity is thin so the 25% volume limit slows any draw, and a delisting event would end the agreement automatically. The company is restricted from most other variable-rate transactions during the term. Proceeds are intended for product candidates and working capital, and the company has not issued a release attributing the move to any other event.

Innventure (NASDAQ:INV): an ATM beside a USD 41.5 million cash balance

Innventure (NASDAQ:INV), a company that builds technology businesses including Accelsius, AeroFlexx and Refinity, fell about 10% to near USD 0.29 in early trading on Monday, October 26, 2026, with prices intraday. The company has not issued a release explaining the move. On Thursday, October 8, 2026 it set up an at-the-market programme of up to USD 60 million and discontinued its standby equity purchase agreement with YA II PN. Market capitalisation is about USD 26 million, and the shares fell about 55% on the day second-quarter results were released in August.

An at-the-market programme lets a company sell shares into the market at its discretion, with no obligation to sell, so supply can rise whenever the price is under USD 1.00 and more shares are needed per dollar raised. The company used USD 59.5 million of cash in operations in the first half of 2026 and ended the second quarter with USD 41.5 million. Second-quarter revenue was USD 953 thousand against a net loss of USD 34.9 million, and the company suspended its previously communicated 2026 revenue and cash flow expectations for Accelsius.

The Board is exploring debt, equity and asset monetisation, and Refinity stops receiving balance sheet funding after the third quarter of 2026. The lead plaintiff period in a securities class action ends on Tuesday, October 27, 2026, and the claims are unproven. Parent-level quarterly cash expenses were cut from USD 7.5 million to USD 4.5 million, and third-quarter results are due in November 2026.

authID (NASDAQ:AUID): convertible debentures that set a ceiling

authID Inc. (NASDAQ:AUID), a provider of identity authentication software, traded about 11.22% lower at an intraday price below USD 0.40 in early trading on Monday, October 26, 2026. The company has not issued a release explaining the move. Its release of Monday, October 5, 2026 priced a private placement of senior secured convertible debentures for gross proceeds of approximately USD 1,350,000, before placement agent fees. The debentures convert at the holder's option at USD 0.386 per share, and the company agreed to file registration statements for resale.

At that price the full amount would convert into about 3.5 million shares, calculated from the published terms. Warrants carry a USD 0.50 exercise price and need stockholder approval before exercise, which keeps a second layer of supply in reserve. Holders of the April 2026 debentures agreed to extend maturity to Sunday, February 28, 2027, which places repayment or refinancing inside the next five months.

A USD 2 million agreement with the EinStrong Foundation, announced on Tuesday, October 6, 2026, supports the revenue case but does not remove the overhang. Proceeds of the financing are intended for working capital and general corporate purposes, a wording that gives no specific growth use. The release did not disclose cash or balance sheet figures, so the funding runway cannot be measured from it, and sub-dollar pricing can bring minimum bid notices under the exchange rules. Third-quarter results have not been dated by the company, and the stockholder vote on the warrants and the resale registration statement are the next steps.

Where Things Stand

The answer is that standby equity gives small companies cash on the buyer's pricing terms, so supply of new shares follows the share price. Traws Pharma (NASDAQ:TRAW) holds a right to sell up to USD 50 million, but the 19.99% cap limits near-term proceeds to about USD 1.1 million at current prices. Innventure (NASDAQ:INV) has USD 41.5 million of cash against heavy operating use and a USD 60 million programme, and authID (NASDAQ:AUID) has debentures convertible at USD 0.386 that cap rallies. The next catalysts are the Innventure lead plaintiff deadline on Tuesday, October 27, 2026, the Federal Reserve decision on Wednesday, October 28, 2026, the first Traws draw, the authID warrant vote and third-quarter reports. Financing terms are not cash received, micro cap shares are volatile, and this is not investment advice.